文献速递银屑病与炎症性皮肤病

托法替布治疗中重度慢性斑块状银屑病患者:开放标签延伸研究的长期安全性与疗效

Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study.
PubMed 文献 · Br J Dermatol · 2018-08-13

报告托法替布治疗中重度慢性斑块状银屑病开放标签延伸研究的最终安全性与疗效数据。2867例患者接受托法替布10 mg每日两次至第3个月,之后研究者可将剂量调整为5或10 mg每日两次。不良事件报告至第66个月,疗效终点至第54个月,安全性与既往III期研究相似,疗效持续至第54个月。

要点

  • 2867例患者接受托法替布,中位治疗时长35.6个月,不良事件报告至第66个月。
  • 严重感染发生率为1.16例/100患者年,恶性肿瘤为0.67,主要不良心血管事件为0.26。
  • 至第54个月各访视点,52%–62%患者达到PGA应答,56%–74%患者达到PASI 75。

核心结论

  • 托法替布治疗银屑病66个月的安全性特征与既往III期研究相似,疗效持续至54个月。

研究设计与样本

  • 开放标签延伸研究,纳入完成合格II/III期托法替布研究的成人中重度慢性斑块状银屑病患者,共2867例接受托法替布治疗。
  • 患者先接受托法替布10 mg每日两次至第3个月,随后研究者可将剂量调整为5或10 mg每日两次。
  • 不良事件报告至第66个月,实验室数据至第54个月。

主要发现

  • 中位治疗时长为35.6个月。
  • 不良事件发生率为82.5%,严重不良事件为13.7%,13.9%患者因不良事件停药,29例患者死亡。
  • 严重感染发生率为1.16例/100患者年,恶性肿瘤为0.67例/100患者年,主要不良心血管事件为0.26例/100患者年。
  • 在合格研究中出现初始变化后,大多数实验室参数在54个月内总体稳定。
  • 至第54个月各访视点,52%–62%患者达到PGA应答(清除或几乎清除),56%–74%患者达到PASI 75。

关键数值与推荐

  • PGA应答定义为医师全局评估为清除或几乎清除。
  • PASI 75定义为银屑病面积与严重程度指数改善75%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor. Final safety and efficacy data from an open-label extension study of tofacitinib in psoriasis are reported. OBJECTIVES: To evaluate the long-term safety and durability of efficacy of tofacitinib in adults with moderate-to-severe chronic plaque psoriasis. METHODS: Eligible patients who completed qualifying phase II/III tofacitinib studies received tofacitinib 10 mg twice daily (q12h) until month 3; subsequently, the dose could be adjusted by investigators to either 5 or 10 mg q12h. Adverse events (AEs) are reported up to month 66 and laboratory data up to month 54. Efficacy end points up to month 54 included Physician's Global Assessment of 'clear' or 'almost clear' (PGA response) and 75% improvement in Psoriasis Area and Severity Index (PASI 75). RESULTS: Overall, 2867 patients received tofacitinib, with a median treatment duration of 35·6 months. Adverse events (AEs) and serious AEs were reported in 82·5% and 13·7% of patients, respectively; 13·9% of patients discontinued owing to AEs; and 29 patients died. Incidence rates (patients with event/100 patient-years) were 1·16 for serious infections, 0·67 for malignancies and 0·26 for major adverse cardiovascular events. After initial changes in qualifying studies, most laboratory parameters were generally stable over 54 months. PGA response was achieved by 52-62% of patients and PASI 75 by 56-74% of patients at each study visit through month 54. CONCLUSIONS: In patients with psoriasis, the safety profile of tofacitinib over 66 months was similar to previous reports in phase III studies and efficacy was sustained through 54 months (NCT01163253).

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Valenzuela F, Korman NJ, Bissonnette R, et al. Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study. Br J Dermatol. 2018. PMID: 29782642. doi:10.1111/bjd.16798

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。